Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 2,209 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Melanoma Neoplasms Clear all

Conditions: Unresectable or Metastatic Melanoma
Interventions: Nivolumab, Ipilimumab, Placebo for Nivolumab, Placebo for Ipilimumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 945 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 46
States / cities: Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 35 more

Conditions: Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm, Melanoma, Renal Cell Carcinoma
Interventions: Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy; Procedure · Other · Radiation
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Duarte, California • Irvine, California

Conditions: Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma, Ras (Kras or Nras) Gene Mutation, BRAF Gene Mutation, CRAF Gene Mutation, Non-Small Cell Lung Carcinoma, Thyroid Carcinoma, Gliomas, Malignant
Interventions: IK-595; Drug
Lead sponsor: Ikena Oncology; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 15
States / cities: Duarte, California • Orange, California • Denver, Colorado + 12 more

Conditions: Advanced Melanoma, Cancer
Interventions: Tesetaxel; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Renal Cell Carcinoma, Small-cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Merkel Cell Carcinoma
Interventions: GEN-011, IL-2, Fludarabine, Cyclophosphamide; Biological · Drug
Lead sponsor: Genocea Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Gilbert, Arizona • Tampa, Florida • Chicago, Illinois + 4 more

Conditions: Malignant Melanoma, Neoplasm Metastasis
Interventions: CP-4055 (ELACYT); Drug
Lead sponsor: Clavis Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Interventions: RMC-6236; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 754 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 21
States / cities: Orange, California • Santa Monica, California • Tampa, Florida + 16 more

Conditions: Uveal Neoplasms, Choroid Neoplasms, Iris Neoplasms
Interventions: Fine needle aspiration biopsy; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer, Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer, Cancer of Neuro-onc, Parathyroid, Desmoid Tumors, Melanoma Cancer
Interventions: data collection; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Melanoma
Interventions: Ipilimumab, Temozolomide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Neoplasm, Lymphoma, Melanoma, Fluorodeoxyglucose, Positron-emission Tomography
Interventions: uEXPLORER/mCT, mCT/uEXPLORER; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Melanoma
Interventions: Not listed
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Melanoma
Interventions: CC-122, Nivolumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Uveal Melanoma, Metastatic
Interventions: Dexamethasone; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Advanced Cancer, Metastatic Melanoma, Metastatic Non-small Cell Lung Cancer, Colorectal Cancer
Interventions: LY3214996, Midazolam, Abemaciclib, Nab-paclitaxel, Gemcitabine, Encorafenib, Cetuximab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Sarasota, Florida • Boston, Massachusetts + 4 more

Conditions: Non-melanoma Skin Cancer
Interventions: Solaraze and Vaniqa; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Birmingham, Alabama

Conditions: Melanoma
Interventions: NY-ESO-1 protein; Poly-ICLC; Montanide; Biological
Lead sponsor: Nina Bhardwaj; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer
Interventions: GSK1120212; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 7
States / cities: Los Angeles, California • Aurora, Colorado • New York, New York + 3 more

Conditions: Melanoma (Skin)
Interventions: cisplatin, sorafenib tosylate, tamoxifen citrate, adjuvant therapy; Drug · Procedure
Lead sponsor: San Diego Pacific Oncology & Hematology Associates; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Encinitas, California

Conditions: Metastatic Uveal Melanoma
Interventions: Nivolumab, Relatlimab; Drug
Lead sponsor: Jose Lutzky, MD; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer, Post Anti-PD-1 Melanoma, 2L+ Cervical Cancer, Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Small Cell Lung Cancer, Third Line or Later (3L+) HER2+ Breast Cancer, Second or Third Line (2L/3L) Cervical Cancer, Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
Interventions: TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug, TransCon TLR7/8 Agonist, Surgery, Trastuzumab, Trastuzumab emtansine (T-DM1); Drug · Procedure
Lead sponsor: Ascendis Pharma Oncology Division A/S; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 14
States / cities: Los Angeles, California • Springfield, Illinois • Louisville, Kentucky + 10 more

Conditions: Melanoma (Skin)
Interventions: MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, recombinant interferon alfa, sargramostim, tyrosinase peptide; Biological
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 32
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Decatur, Georgia + 24 more

Conditions: Melanoma, Advanced Melanoma
Interventions: Biopsy, Biospecimen Collection; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Familial Pancreatic Cancer
Interventions: biologic sample preservation procedure, medical chart review, survey administration; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 1,122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Phase II Study of Tesetaxel in Metastatic Melanoma

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

Clinical Study of Previously Untreated Patients With Malignant Melanoma

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Validation of a Molecular Prognostic Test for Eye Melanoma

Optional Sub-study to Intraoperative Imaging With ICG Registry

Ipilimumab + Temozolomide in Metastatic Melanoma

Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma

Pilot Study of Infrared Imaging of Cutaneous Melanoma

Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma

Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer

Safety Study of Adjuvant Vaccine to Treat Melanoma Patients

Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma

Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma

Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma

Collecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and Melanoma